Selective 3-hydroxylation deficiency of lidocaine and its metabolite in Dark Agouti rats
- 15 July 1991
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 42 (3) , 693-695
- https://doi.org/10.1016/0006-2952(91)90333-z
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Metabolism of Lidocaine in Human Liver in VitroActa Pharmacologica et Toxicologica, 2009
- Simultaneous Quantitation of Lidocaine and Its Four Metabolites by High-performance Liquid Chromatography: Application to studies on In Vitro and In Vivo Metabolism of Lidocaine in RatsJournal of Pharmaceutical Sciences, 1985
- Age associated alteration of lidocaine metabolism is position selectiveBiochemical and Biophysical Research Communications, 1985
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Precursor–Metabolite Interaction in the Metabolism of LidocaineJournal of Pharmaceutical Sciences, 1984
- In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquineCanadian Journal of Physiology and Pharmacology, 1982
- Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strainsJournal of Pharmacy and Pharmacology, 1981
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Evidence for Two Catalytically Different Binding Sites of Liver Microsomal Cytochrome P‐450: Importance for Species and Sex Differences in Oxidation Pattern of LidocaineActa Pharmacologica et Toxicologica, 1977